ECHO Autism STAT: Accelerating Early Access to Autism Diagnosis / M. O. MAZUREK in Journal of Autism and Developmental Disorders, 49-1 (January 2019)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 49-1 (January 2019) . - p.127-137 Titre : ECHO Autism STAT: Accelerating Early Access to Autism Diagnosis Type de document : Texte imprimé et/ou numérique Auteurs : M. O. MAZUREK, Auteur ; A. CURRAN, Auteur ; Courtney BURNETTE, Auteur ; K. SOHL, Auteur Article en page(s) : p.127-137 Langues : Anglais (eng) Mots-clés : Autism  Autism spectrum disorder  Health care access  Primary care provider  Screening Index. décimale : PER Périodiques Résumé : Although early diagnosis of autism is critical for promoting access to early intervention, many children experience significant diagnostic delays. Shortages of healthcare providers, limited capacity at autism centers, and geographic and socioeconomic challenges contribute to these delays. The current pilot study examined the feasibility of a new model for training community-based primary care providers (PCPs) in underserved areas in screening and diagnosis of young children at highest risk for autism. By combining hands-on training in standardized techniques with ongoing virtual mentorship and practice, the program emphasized both timely diagnosis and appropriate referral for more comprehensive assessment when necessary. Results indicated improvements in PCP practice and self-efficacy, and feasibility of the model for enhancing local access to care. En ligne : http://dx.doi.org/10.1007/s10803-018-3696-5 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=376 [article] ECHO Autism STAT: Accelerating Early Access to Autism Diagnosis [Texte imprimé et/ou numérique] / M. O. MAZUREK, Auteur ; A. CURRAN, Auteur ; Courtney BURNETTE, Auteur ; K. SOHL, Auteur . - p.127-137. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 49-1 (January 2019) . - p.127-137 Mots-clés : Autism  Autism spectrum disorder  Health care access  Primary care provider  Screening Index. décimale : PER Périodiques Résumé : Although early diagnosis of autism is critical for promoting access to early intervention, many children experience significant diagnostic delays. Shortages of healthcare providers, limited capacity at autism centers, and geographic and socioeconomic challenges contribute to these delays. The current pilot study examined the feasibility of a new model for training community-based primary care providers (PCPs) in underserved areas in screening and diagnosis of young children at highest risk for autism. By combining hands-on training in standardized techniques with ongoing virtual mentorship and practice, the program emphasized both timely diagnosis and appropriate referral for more comprehensive assessment when necessary. Results indicated improvements in PCP practice and self-efficacy, and feasibility of the model for enhancing local access to care. En ligne : http://dx.doi.org/10.1007/s10803-018-3696-5 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=376

Evidence-based use of scalable biomarkers to increase diagnostic efficiency and decrease the lifetime costs of autism / T. W. FRAZIER in Autism Research, 14-6 (June 2021)  

Public ISBD [article]  inAutism Research > 14-6 (June 2021) . - p.1271-1283 Titre : Evidence-based use of scalable biomarkers to increase diagnostic efficiency and decrease the lifetime costs of autism Type de document : Texte imprimé et/ou numérique Auteurs : T. W. FRAZIER, Auteur ; D. L. COURY, Auteur ; K. SOHL, Auteur ; Kayla E. WAGNER, Auteur ; R. UHLIG, Auteur ; S. D. HICKS, Auteur ; F. A. MIDDLETON, Auteur Article en page(s) : p.1271-1283 Langues : Anglais (eng) Mots-clés : Autism Spectrum Disorder/diagnosis  Autistic Disorder  Biomarkers  Child  Early Diagnosis  Humans  Mass Screening  United States  autism spectrum disorder  biomarkers  cost analysis  early diagnosis  evidence-based assessment  developer of the eye tracking test that was used in the EBM analysis. Thomas W.  Frazier has received federal funding or research support from, acted as a consultant  to, received travel support from, and/or received a speaker's honorarium from  Quadrant Biosciences, Impel NeuroPharma, F. Hoffmann?La Roche AG Pharmaceuticals,  the Cole Family Research Fund, Simons Foundation, Ingalls Foundation, Forest  Laboratories, Ecoeos, IntegraGen, Kugona LLC, Shire Development, Bristol?Myers  Squibb, Roche Pharma, National Institutes of Health, and the Brain and Behavior  Research Foundation and has an investor stake in AutismEYES LLC. Steven D. Hicks and  Frank A. Middleton are co?developers of the saliva RNA based autism test that is  used in the EBM analysis, and members of the Clinical and Scientific Advisory Boards  of Quadrant Biosciences. Kristin Sohl is director of ECHO Autism and both Kristin  Sohl and Daniel L. Coury are a member of the Clinical Advisory Board of Quadrant  Biosciences. Daniel L. Coury has received federal funding or research support from  National Institutes of Health, GW Biosciences, Neurim, Stemina Biosciences, and  Stalicla SA  and acted as a consultant to BioRosa, Cognoa, GW Biosciences, and  Stalicla SA. Kayla E. Wagner and Richard Uhlig are employees of Quadrant  Biosciences. Quadrant Biosciences holds patent rights and exclusive sales rights for  the Clarifi ASD saliva test. Index. décimale : PER Périodiques Résumé : Challenges associated with the current screening and diagnostic process for autism spectrum disorder (ASD) in the US cause a significant delay in the initiation of evidence-based interventions at an early age when treatments are most effective. The present study shows how implementing a second-order diagnostic measure to high risk cases initially flagged positive from screening tools can further inform clinical judgment and substantially improve early identification. We use two example measures for the purposes of this demonstration; a saliva test and eye-tracking technology, both scalable and easy-to-implement biomarkers recently introduced in ASD research. Results of the current cost-savings analysis indicate that lifetime societal cost savings in special education, medical and residential care are estimated to be nearly $580,000 per ASD child, with annual cost savings in education exceeding $13.3 billion, and annual cost savings in medical and residential care exceeding $23.8 billion (of these, nearly $11.2 billion are attributable to Medicaid). These savings total more than $37 billion/year in societal savings in the US. Initiating appropriate interventions faster and reducing the number of unnecessary diagnostic evaluations can decrease the lifetime costs of ASD to society. We demonstrate the value of implementing a scalable highly accurate diagnostic in terms of cost savings to the US. LAY SUMMARY: This paper demonstrates how biomarkers with high accuracy for detecting autism spectrum disorder (ASD) could be used to increase the efficiency of early diagnosis. Results also show that, if more children with ASD are identified early and referred for early intervention services, the system would realize substantial costs savings across the lifespan. En ligne : http://dx.doi.org/10.1002/aur.2498 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=449 [article] Evidence-based use of scalable biomarkers to increase diagnostic efficiency and decrease the lifetime costs of autism [Texte imprimé et/ou numérique] / T. W. FRAZIER, Auteur ; D. L. COURY, Auteur ; K. SOHL, Auteur ; Kayla E. WAGNER, Auteur ; R. UHLIG, Auteur ; S. D. HICKS, Auteur ; F. A. MIDDLETON, Auteur . - p.1271-1283. Langues : Anglais (eng) in Autism Research > 14-6 (June 2021) . - p.1271-1283 Mots-clés : Autism Spectrum Disorder/diagnosis  Autistic Disorder  Biomarkers  Child  Early Diagnosis  Humans  Mass Screening  United States  autism spectrum disorder  biomarkers  cost analysis  early diagnosis  evidence-based assessment  developer of the eye tracking test that was used in the EBM analysis. Thomas W.  Frazier has received federal funding or research support from, acted as a consultant  to, received travel support from, and/or received a speaker's honorarium from  Quadrant Biosciences, Impel NeuroPharma, F. Hoffmann?La Roche AG Pharmaceuticals,  the Cole Family Research Fund, Simons Foundation, Ingalls Foundation, Forest  Laboratories, Ecoeos, IntegraGen, Kugona LLC, Shire Development, Bristol?Myers  Squibb, Roche Pharma, National Institutes of Health, and the Brain and Behavior  Research Foundation and has an investor stake in AutismEYES LLC. Steven D. Hicks and  Frank A. Middleton are co?developers of the saliva RNA based autism test that is  used in the EBM analysis, and members of the Clinical and Scientific Advisory Boards  of Quadrant Biosciences. Kristin Sohl is director of ECHO Autism and both Kristin  Sohl and Daniel L. Coury are a member of the Clinical Advisory Board of Quadrant  Biosciences. Daniel L. Coury has received federal funding or research support from  National Institutes of Health, GW Biosciences, Neurim, Stemina Biosciences, and  Stalicla SA  and acted as a consultant to BioRosa, Cognoa, GW Biosciences, and  Stalicla SA. Kayla E. Wagner and Richard Uhlig are employees of Quadrant  Biosciences. Quadrant Biosciences holds patent rights and exclusive sales rights for  the Clarifi ASD saliva test. Index. décimale : PER Périodiques Résumé : Challenges associated with the current screening and diagnostic process for autism spectrum disorder (ASD) in the US cause a significant delay in the initiation of evidence-based interventions at an early age when treatments are most effective. The present study shows how implementing a second-order diagnostic measure to high risk cases initially flagged positive from screening tools can further inform clinical judgment and substantially improve early identification. We use two example measures for the purposes of this demonstration; a saliva test and eye-tracking technology, both scalable and easy-to-implement biomarkers recently introduced in ASD research. Results of the current cost-savings analysis indicate that lifetime societal cost savings in special education, medical and residential care are estimated to be nearly $580,000 per ASD child, with annual cost savings in education exceeding $13.3 billion, and annual cost savings in medical and residential care exceeding $23.8 billion (of these, nearly $11.2 billion are attributable to Medicaid). These savings total more than $37 billion/year in societal savings in the US. Initiating appropriate interventions faster and reducing the number of unnecessary diagnostic evaluations can decrease the lifetime costs of ASD to society. We demonstrate the value of implementing a scalable highly accurate diagnostic in terms of cost savings to the US. LAY SUMMARY: This paper demonstrates how biomarkers with high accuracy for detecting autism spectrum disorder (ASD) could be used to increase the efficiency of early diagnosis. Results also show that, if more children with ASD are identified early and referred for early intervention services, the system would realize substantial costs savings across the lifespan. En ligne : http://dx.doi.org/10.1002/aur.2498 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=449

Rethinking autism spectrum disorder assessment for children during COVID-19 and beyond / Lonnie ZWAIGENBAUM in Autism Research, 14-11 (November 2021)  

Public ISBD [article]  inAutism Research > 14-11 (November 2021) . - p.2251-2259 Titre : Rethinking autism spectrum disorder assessment for children during COVID-19 and beyond Type de document : Texte imprimé et/ou numérique Auteurs : Lonnie ZWAIGENBAUM, Auteur ; Somer L. BISHOP, Auteur ; W. L. STONE, Auteur ; L. IBANEZ, Auteur ; Alycia K. HALLADAY, Auteur ; S. GOLDMAN, Auteur ; A. KELLY, Auteur ; C. KLAIMAN, Auteur ; Meng-Chuan LAI, Auteur ; M. MILLER, Auteur ; Celine A. SAULNIER, Auteur ; P. SIPER, Auteur ; K. SOHL, Auteur ; Zachary WARREN, Auteur ; Amy M. WETHERBY, Auteur Article en page(s) : p.2251-2259 Langues : Anglais (eng) Mots-clés : Autism Spectrum Disorder/diagnosis/epidemiology  Autistic Disorder  Covid-19  Child  Humans  Pandemics  SARS-CoV-2  assessment  autism  challenges  children  diagnosis  disparities  pandemic Index. décimale : PER Périodiques Résumé : The COVID-19 pandemic has posed unique challenges for families and caregivers, as well as for autism-focused clinicians, who are faced with providing a thorough and accurate evaluation of children's specific needs and diagnoses in the absence of in-person assessment tools. The shift to telehealth assessments has challenged clinicians to reconsider approaches and assumptions that underlie the diagnostic assessment process, and to adopt new ways of individualizing standard assessments according to family and child needs. Mandates for physical distancing have uncovered deficiencies in diagnostic practices for suspected autism and have illuminated biases that have posed obstacles preventing children and families from receiving the services that they truly need. This Commentary outlines several considerations for improving diagnostic practices as we move forward from the current pandemic and continue to strive to build an adaptable, sustainable, equitable, and family-centered system of care. LAY SUMMARY: Physical distancing and the abrupt end to in-person services for many children on the autism spectrum has forced clinicians to examine the existing challenges with autism spectrum disorder (ASD) diagnostic assessment and consider things they want to keep and things that should be changed in the years ahead. New approaches such as telehealth both alleviated and exacerbated existing disparities, and brought into stark focus the importance of equitable and timely access to family-centered care. This commentary suggests ways of improving clinical practices related to ASD assessment to continue along this path. En ligne : http://dx.doi.org/10.1002/aur.2615 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=450 [article] Rethinking autism spectrum disorder assessment for children during COVID-19 and beyond [Texte imprimé et/ou numérique] / Lonnie ZWAIGENBAUM, Auteur ; Somer L. BISHOP, Auteur ; W. L. STONE, Auteur ; L. IBANEZ, Auteur ; Alycia K. HALLADAY, Auteur ; S. GOLDMAN, Auteur ; A. KELLY, Auteur ; C. KLAIMAN, Auteur ; Meng-Chuan LAI, Auteur ; M. MILLER, Auteur ; Celine A. SAULNIER, Auteur ; P. SIPER, Auteur ; K. SOHL, Auteur ; Zachary WARREN, Auteur ; Amy M. WETHERBY, Auteur . - p.2251-2259. Langues : Anglais (eng) in Autism Research > 14-11 (November 2021) . - p.2251-2259 Mots-clés : Autism Spectrum Disorder/diagnosis/epidemiology  Autistic Disorder  Covid-19  Child  Humans  Pandemics  SARS-CoV-2  assessment  autism  challenges  children  diagnosis  disparities  pandemic Index. décimale : PER Périodiques Résumé : The COVID-19 pandemic has posed unique challenges for families and caregivers, as well as for autism-focused clinicians, who are faced with providing a thorough and accurate evaluation of children's specific needs and diagnoses in the absence of in-person assessment tools. The shift to telehealth assessments has challenged clinicians to reconsider approaches and assumptions that underlie the diagnostic assessment process, and to adopt new ways of individualizing standard assessments according to family and child needs. Mandates for physical distancing have uncovered deficiencies in diagnostic practices for suspected autism and have illuminated biases that have posed obstacles preventing children and families from receiving the services that they truly need. This Commentary outlines several considerations for improving diagnostic practices as we move forward from the current pandemic and continue to strive to build an adaptable, sustainable, equitable, and family-centered system of care. LAY SUMMARY: Physical distancing and the abrupt end to in-person services for many children on the autism spectrum has forced clinicians to examine the existing challenges with autism spectrum disorder (ASD) diagnostic assessment and consider things they want to keep and things that should be changed in the years ahead. New approaches such as telehealth both alleviated and exacerbated existing disparities, and brought into stark focus the importance of equitable and timely access to family-centered care. This commentary suggests ways of improving clinical practices related to ASD assessment to continue along this path. En ligne : http://dx.doi.org/10.1002/aur.2615 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=450

---

1 (1 - 3 / 3)